Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nice volume again today... could we see something next week??? Hoping we get the fins next week or some type of update would be nice !!
PLEASE tell us ALL how you know what is going on w/ NYACRES and MCIG???
i assume these CRYO pics in China are fake too? LMAO !!!
http://www.americancryostem.com/china-press-tour/
bighdaddie,
Agreed !!
nice pics of CRYO executives in China
http://www.americancryostem.com/china-press-tour/
News out American CryoStem Announces Launch of ATGRAFT(TM) in China
American CryoStem Announces Launch of ATGRAFT(TM) in China
EATONTOWN, NJ / ACCESSWIRE / July 12, 2018 / American CryoStem Corporation (OTC PINK: CRYO), a leading strategic application developer, marketer, and global licensor of patented adipose tissue-based cellular technologies, for the Regenerative and Personalized Medicine industries, today announced the national launch of CRYO's ATGRAFTTM tissue collection, processing and storage technology by Baoxin Asia Pacific Biotechnology (Shenzhen) Co. Ltd. ("Baoxin") in China. John Arnone, CEO and Anthony Dudzinski, COO, of CRYO traveled throughout south east China with the management and marketing team of Baoxin to present the ATGRAFTTM platform to leading plastic and cosmetic surgery hospitals in Shenzhen, Nanning, Guangzhou, Guangxi and Changsha. Additionally, Mr. Arnone and Mr. Dudzinski, attended the signing of investment documents between Baoxin and Chinese government and Banking officials in Shenzhen, China as well as the official launch presentation and evening gala hosted by Baoxin in Shenzhen. Baoxin is being financed by a combination of China's CITIC Group and the China Development Bank.
American CryoStem Corporation is one of the largest commercial personal tissue banks globally, focused exclusively on the processing and storage of adipose tissue and the regenerative cells the tissue contains. The China launch activities are in support of the Company's previously announced licensing and supply agreement with Baoxin, under which Baoxin will pay the Company a minimum annual guarantee against a fixed fee per process and purchase certain necessary consumables from CRYO required for the collection, processing and storage of the collected adipose tissue. Under the terms of the Agreements signed in Fiscal 2017, CRYO invested in and currently holds five percent (5%) of Baoxin shares. Additionally, Mr. Arnone and Mr. Dudzinski were elected to serve as Directors of Baoxin during their visit to Shenzhen, China.
The Company's management presented an overview of the ATGRAFTTM products and technologies to MOII Plastic Surgery Hospital and Fuhua Plastic & Aesthetic Hospital in Schenzhen, GuangMei Plastic Surgery Hospital and UBeauty Hospital in Guangzhou, AIST Plastic Surgery Hospital and, HauMei Plastic Surgery Hospital in Guangxi and the Nanning Beautiful Focus Cosmetology Hospital in Nanning, and the Yamei Aesthetic and Plastic Surgery Hospital In Changsha. Additionally, the Company participated in a press conference following Baoxin's financing signing ceremony at the government building in Shenzhen and presented at the Baoxin dinner launch event featuring major health and cosmetic surgery industry organizations in China. Event photos can be found by following this link: American CryoStem ATGRAFT launch in China
https://www.accesswire.com/users/newswire/images/505048/77FBEBAE.jpg
"We were very impressed with the Baoxin, ATGRAFTTM marketing program and work ethic and would like to congratulate Baoxin's management and marketing staff for a very impressive and effective launch tour," commented John Arnone, CEO, "the professionalism and interest generated in the ATGRAFTTM product prior to our arrival contributed greatly to the successful presentation at each hospital. We were also impressed by the organization and scale of the facilities we visited, each facility provides a wide range of cosmetic, aesthetic, and plastic surgical services in a single facility of ten to thirty thousand square meters, these are large facilities located in very large cities with heavy patient flow."
Anthony Dudzinski, COO commented "The Chinese aesthetic, cosmetic and plastic surgery hospital facilities in China are organized differently than the way these services are delivered in the US. Each hospital facility provides every cosmetic option for a patient from surgical augmentations to cosmetic dentistry. We believe that this organization style is perfectly designed to rapidly expand Baoxin's success with the ATGRAFTTM products and allow the Chinese to prepare for the future of regenerative and cellular therapies. Further, management believes that China may become one of the largest markets in the world for tissue transfer and regenerative medicine."
Trip photos may be found at http://www.americancryostem.com/china-press-tour/ or via Google Photos
About American CryoStem Corporation
American CryoStem Corporation (OTC PINK: CRYO); founded in 2008, is a biotechnology pioneer, standardizing adipose tissue (fat) derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, laboratory in New Jersey and licensed laboratories in Hong Kong, Bangkok, Thailand, China and Tokyo, Japan, which operate on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue and adipose derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology which supports a growing pipeline of stem cell applications and biologic products. We are leveraging our platform and a developed product portfolio to create a global footprint of licensed laboratory affiliates, domestic and international physicians networks and research organizations who purchase tissue collection, processing and storage consumables from CRYO. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC's) derived from adipose tissue that work in conjunction with our patented (non-animal) medium lines. The Company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
For further detailed Corporate or Regenerative Medicine information please visit:
www.americancryostem.com, request by email at info@americancryostem.com or phone 732-747-1007
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
SOURCE: American CryoStem Corporation
© Copyright 2018 ACCESSWIRE. All Rights Reserved.
no to both... ty for asking !!
PLEASE explain your theory that MCIG is using OMHE as a dilution machine? and bc OMHE isn't getting back to anyone that it's MCIG's fault and why MCIG will be purchased by the Russians?
yet w/ all you mentioned regarding MCIG, you are still here posting..LMAO !! Do you even own shares in MCIG? just curious?
Hanging your hopes on Sassano?!?!?! LMAO !!!
Good luck w/ that!! We will see how good of a character witness Sassano is under oath as a former MCIG contractor when the DIRT starts flying...
im sure they are ready... can't wait till they get to the deposition part to see how Sassano does under oath!!
IMO, Sassano might have some alleged character / alleged business skeletons in his closet that could come out in the future..
Crow, im up ty for asking... How many MCIG shares do you own again??
Have you called Sassano yet?
btw- didnt you state MCIG would be going back to the teens recently?
wow, still bringing things up about MCIG from 2 years ago..
It's hard to believe someone has been here for so long w/ ZERO shares in MCIG???
You are so good at finding things out about MCIG, as mentioned before when you chat w/ him, ask him about it and see what his response is??
ask your buddy Sassano how many people he pissed off while ALLEGEDLY drinking /ALLEGEDLY being drunk on his so called rants to former MCIG Employees/Contractors/Partners while he worked / represented MCIG ...
I cant wait to hear from Former MCIG Employees/Contractors/Partners testify about the character of Sassano while he was with MCIG... IMO it will be HILARIOUS !!
Have you done that yet?
got it.. it doesn't take this long to get fins audited just my opinion...
Are you saying you know the fins are done?
might even be 20/20...lol
Expert witness for Sassano vs MCIG lawsuit?? LMAO !!
MCIG is late to the game !! LMAO !!
Let's look back over the years....Yahoo was first to market and then came google... MSFT then came APPLE.... MSFT Databases then came Oracle...the example goes on and on and on !! all companies were already in business but APPARENTLY were late to the game. lol
IMO, it's BETTER for MCIG to be in the CBD market then not to be in the CBD market.
no matter what MCIG accomplishes the same people say the same thing OVER and OVER.
It should NOT take this long for audited fins !!
Not to be rude, but...DOES it CURE communication between the company, Market and shareholders??
PLEASE provide any and ALL proof of your alleged
How_Many_Hemp_Contracts_Sold_By_Fake_95_Boots_on_Ground? 0?
MCIG social media... https://www.facebook.com/mCigInc/videos/2266416213369352/
Looks like NY acres is GROWING !! and we will still hear people doubt them...
maybe some audited financials ?? !!
if CRYO admits it, why are you still posting OLD news from CRYO??
Bighdaddie,
CRYO is REAL and should be moving higher !!
ZERO proof and alleges CRYO its a scam??
nice volume today !!
NO PROOF on MCIG pump and dump...LMAO !!! another MCIG BS claim when the stock rises... PLEASE explain to all of us if NOTHING is for free and you DO NOT have a position... why are you on the MCIG board again??
NO PROOF of a MCIG pump and dump ... Keep making things up about MCIG w/ ZERO PROOF AND ZERO shares owned of MCIG...
nice bids on CRYO..
NEWS out https://www.otcmarkets.com/stock/CRYO/news/story?e&id=1109464
American CryoStem to Develop Standardized Tissue Scoring System
EATONTOWN, NJ / ACCESSWIRE / June 19, 2018 / American CryoStem Corporation (OTC PINK: CRYO), a leading strategic application developer, marketer, global licensor of patented adipose tissue-based cellular technologies, for the Regenerative and Personalized Medicine industries, today announced a new scientific project to create a Histological Scoring System for Collected Lipoaspirate. This project is based upon the Company's extensive experience with its ATGRAFT™ product and requests from the physician community to provide additional data related to the results of different tissue harvesting techniques, processing, storage and post-storage tissue and cell viability. The Company's Chief Scientific Officer, Michael Moeller, Ph.D., will be performing the study with the assistance of the Histology Core at Rutgers University in New Jersey.
American CryoStem Corporation is one of the premier commercial personal tissue banks, globally focused exclusively on the processing and storage of adipose tissue and the regenerative cells the tissue contains. Adipose tissue is a loose connective body tissue in which adipocytes (fat cells) and other cell types are held together by connective tissue fibers. Data published to date indicates that properly-collected lipoaspirates maintain some semblance of tissue structure, although the method of collection can strongly impact the quality of that tissue structure. This project is designed to build upon the Company's ongoing research and development by measuring how much of this loose tissue structure is retained during tissue harvest and following cryopreservation and subsequent thawing. The Company will be subjecting the collected tissue to histological analysis, at collection, following processing prior to cryopreservation and after thawing.
"We are excited about beginning work on this 'Tissue Scoring System' (TSS)," said Chief Scientific Officer Michael Moeller, Ph.D.
"TSS will permit us to perform qualitative and semi-quantitative evaluations of incoming adipose tissue samples and support more precise quality evaluations of our final ATGRAFT™ product. TSS will also augment our current cell-based tracking of the quality of the incoming adipose tissue samples and will be based on established histological criteria that will consider the tissue quality as a whole. TSS will permit tracking of a sample's quality throughout the processing, storage, and post-cryopreservation stages, and will provide criteria for direct comparisons between theses stages. Over the years, we also have observed that certain lipoaspirate collection methods seem to result in poorer quality samples, and this system will permit us to comprehensively define those changes in quality to physicians. This system will also permit us to provide meaningful, detailed feedback to physicians regarding the quality of their collection technique, helping them to provide better and more robust samples, and provide additional quality assurance metrics about their returned ATGRAFT™ samples."
Anthony Dudzinski commented: "The concept of a scoring system as devised by our Chief Scientific Officer, Michael Moeller, Ph.D., will provide a unique opportunity for the Company to improve outcomes for our clients by providing comparative data to our physician network. In January 2018, we began reviewing data from hundreds of adipose tissue processes and storages processed in our U.S. laboratory. Our scientific team, led by Dr. Moeller, plans to begin publishing White Papers and release related scientific data regarding the collection-processing-storage and post-thaw viability of adipose tissue and the regenerative cells contained in the stored tissue. Additionally, we will be working with the Histology Core at Rutgers to perform the histology analysis and create the Scoring System that can 'grade' the quality of the tissue we receive and process."
About American CryoStem Corporation
American CryoStem Corporation (OTC PINK: CRYO); founded in 2008, is a biotechnology pioneer, standardizing adipose tissue (fat) derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, laboratory in New Jersey and licensed laboratories in Hong Kong, Bangkok, Thailand, China and Tokyo, Japan, which operate on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue and adipose-derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology which supports a growing pipeline of stem cell applications and biologic products. We are leveraging our platform and a developed product portfolio to create a global footprint of licensed laboratory affiliates, domestic and international physicians networks and research organizations who purchase tissue collection, processing, and storage consumables from CRYO. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC's) derived from adipose tissue that work in conjunction with our patented (non-animal) medium lines. The Company's R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
For further detailed Corporate or Regenerative Medicine information please visit:
www.americancryostem.com
request by email at info@americancryostem.com, or 732-747-1007
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation's ("the Company") future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries, and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
SOURCE: American CryoStem Corporation
© Copyright 2018 ACCESSWIRE. All Rights Reserved.
i answered YOUR question the first time you asked it..smh... go back and look at my response !!
Bubba,
did your bubble burst with MCIG ?? haven't heard from you lately????
btw- where is 1vaman on the UPSIDE of MCIG !!!
I'm shocked we on the MCIG board havent heard a PEEP from you both w/ the up turn and slight pull back on MCIG??
We all miss your MCIG information???
has anyone seen or heard from Bubba. SILENCE as it moves up...hmmm...